Mary Grizzard
Family · Franklin, TNNPI 1821509266
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Pfizer accounts for 84.8% of it on its own, with 41 other manufacturers making up the rest. 2025 is the largest year on record at $40,084, more than ten times the $1,676 reported in 2021. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $250.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$55K
- Array Biopharma Inc$2K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$887
- Daiichi Sankyo Inc.$591
- Johnson & Johnson$471
- plus $4K from 36 others
Across 1 payment — averaging $780.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$780
What the payments were for
- Consulting fees$5,5409%
- Speaking & faculty fees$37,33058%
- Travel & lodging$13,40621%
- Food & beverage$8,31713%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,791 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 30 | $18,179 |
| Morphine Sulfate ErMorphine Sulfate | 34 | $575 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $533 |
| Hydroxyurea | 21 | $379 |
| Gabapentin | 39 | $367 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 13 | $328 |
| Prochlorperazine Maleate | 11 | $289 |
| Ondansetron Hcl | 11 | $219 |
| Prednisone | 28 | $217 |
| Methylphenidate Hcl | 15 | $203 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $162 |
| Oxycodone Hcl | 11 | $154 |
| Levothyroxine Sodium | 27 | $134 |
| Lorazepam | 19 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $471 | $18,17930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Franklin
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.